336 related articles for article (PubMed ID: 26874951)
1. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.
Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Komatsu S; Shiozaki A; Kakihara N; Okamoto K; Taniguchi H; Imoto I; Otsuji E
Gastric Cancer; 2017 Jan; 20(1):126-135. PubMed ID: 26874951
[TBL] [Abstract][Full Text] [Related]
2. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.
Shoda K; Masuda K; Ichikawa D; Arita T; Miyakami Y; Watanabe M; Konishi H; Imoto I; Otsuji E
Gastric Cancer; 2015 Oct; 18(4):698-710. PubMed ID: 25322965
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer.
Imaoka H; Toiyama Y; Okigami M; Yasuda H; Saigusa S; Ohi M; Tanaka K; Inoue Y; Mohri Y; Kusunoki M
Gastric Cancer; 2016 Jul; 19(3):744-53. PubMed ID: 26233325
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR.
Kim B; Nam SK; Seo SH; Park KU; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Sci Rep; 2020 Mar; 10(1):4177. PubMed ID: 32144300
[TBL] [Abstract][Full Text] [Related]
6. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
7. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
8. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
9. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer.
Tsujiura M; Komatsu S; Ichikawa D; Shiozaki A; Konishi H; Takeshita H; Moriumura R; Nagata H; Kawaguchi T; Hirajima S; Arita T; Fujiwara H; Okamoto K; Otsuji E
Gastric Cancer; 2015 Apr; 18(2):271-9. PubMed ID: 24626859
[TBL] [Abstract][Full Text] [Related]
10. A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer.
Saito T; Kurashige J; Nambara S; Komatsu H; Hirata H; Ueda M; Sakimura S; Uchi R; Takano Y; Shinden Y; Iguchi T; Eguchi H; Ehata S; Murakami K; Sugimachi K; Mimori K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S915-22. PubMed ID: 25986864
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital PCR measurement of HER2 in patients with gastric cancer.
Kinugasa H; Nouso K; Tanaka T; Miyahara K; Morimoto Y; Dohi C; Matsubara T; Okada H; Yamamoto K
Br J Cancer; 2015 May; 112(10):1652-5. PubMed ID: 25897674
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
13. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
14. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
15. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression.
Kanda M; Nomoto S; Oya H; Takami H; Shimizu D; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S214-21. PubMed ID: 25743330
[TBL] [Abstract][Full Text] [Related]
16. Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
Tahara T; Tahara S; Horiguchi N; Kawamura T; Okubo M; Ishizuka T; Yamada H; Yoshida D; Ohmori T; Maeda K; Komura N; Ikuno H; Jodai Y; Kamano T; Nagasaka M; Nakagawa Y; Tuskamoto T; Urano M; Shibata T; Kuroda M; Ohmiya N
Anticancer Res; 2017 Apr; 37(4):1997-2001. PubMed ID: 28373473
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
[TBL] [Abstract][Full Text] [Related]
18. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
19. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
20. The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis.
Park KU; Lee HE; Nam SK; Nam KH; Park DJ; Kim HH; Kim WH; Lee HS
Clin Chem Lab Med; 2014 Jul; 52(7):1033-40. PubMed ID: 24670359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]